Eli Lilly to acquire Verve Therapeutics for $1.3bn.

Eli Lilly, a pharmaceutical company, agreed to acquire Verve Therapeutics, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, for $1.3bn. "Lilly is eager to welcome our Verve colleagues to Lilly and continue the development of these promising potential new medicines aimed at improving outcomes for patients with cardiovascular disease and addressing the significant unmet medical need in this space," Ruth Gimeno, Eli Lilly Vice President.